Quest Diagnostics Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while ABRDN Physical Gold Shares ETF trades at $39.92 (market cap $7.03B). The key difference: Quest Diagnostics Inc is far larger — about 3.6× ABRDN Physical Gold Shares ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| DGX | SGOL | |
|---|---|---|
Market Cap | $25.48B | $7.03B |
Volume | 941,866 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $247.45 | $51.41 |
52-Week Low | $173.49 | $37.54 |
Typical Hold Time | 56 Days | 57 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
SGOL trades at $39.92, up 2.31% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks key financial ratio data, making fundamental assessment difficult. Recent news highlights gold's sensitivity to Treasury yields and Fed policy, with prices under pressure from rising rates but finding some support from softer inflation data.
The outlook remains cautious due to bearish technicals and macroeconomic headwinds from interest rates. Investment opportunity hinges on gold's safe-haven appeal if economic uncertainty rises, but risks include persistent rate hikes and dollar strength dampening gold demand. Without current fundamentals, valuation is unclear.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →